2025: The Year That Set the Record Straight for Cannabis Industry

The year 2025 is poised to be remembered as a cornerstone year for the global cannabis industry. It is a year in which some countries achieved the regulatory maturity needed to consolidate their position as key players in the pharmaceutical sector. In contrast, in other countries, cannabis plants saw legal recognition to the extent that it is considered for historic federal reclassification. Yet, 2025 is not just about regulation, it’s about the professionalization of the sector, introducing new technologies for greater operational efficiency and taking the crucial first steps toward its formal integration into global financial systems.

For years, legally-operating US cannabis companies were detained by the IRS Section 280E. This provision, designed to penalize drug traffickers, barred cannabis businesses from deducting most standard business expenses, from rent and utilities to salaries and marketing. This fiscal constraint forced local and international companies to incur substantial federal tax rates, which directly impacted their growth and profitability.

The transition to Schedule III effectively neutralizes the impact of 280E. By allowing companies to deduct standard business expenses, their gross profits translate into genuine net income. This immediate fiscal relief is expected to bring billions of dollars back into the industry, driving immediate income growth and making the sector far more attractive to institutional investors who previously remained on the sidelines. Additionally, it means easing banking restrictions, primarily through the renewed push for the SAFE Banking Act, which offers critical financial certainty, improves access to traditional capital, and accelerates the industry’s integration into the mainstream US economic system. This move fundamentally shifts the perception of cannabis enterprises from legal gray-market businesses to legitimate, profitable, and taxable economic entities. 

The US action on rescheduling and banking will prompt Canada to review its current recreational regulations and product scheduling, likely seeking greater competitiveness against the newly empowered American market. Crucially, it will pressure Mexico to finally issue the much-needed secondary rules for its legal framework, which has recognized cannabis research since 2021 but remains paralyzed by regulatory ambiguity. For regional growth and competitiveness, these three countries must work to harmonize their national regulations with the new US federal framework.

While the United States focuses on commercial cannabis industrialization, Europe continues to review a more controlled, social-centered regulatory model.

To start, Germany solidified its regulatory path, which began in 2024 with the legalization of recreational use and the recognition of non-profit cannabis clubs. The German Cannabis Act has become a driver for other regulations across the European Union, while simultaneously establishing Germany as the continent’s largest and most sophisticated market for medicinal cannabis. The focus is strictly on quality control, consumer protection, and responsible access.

In contrast, Spain focused its advancements on the therapeutic vertical, formally recognizing medicinal cannabis through professional prescription for specific health conditions. This advancement is expected to provide essential aid to over 300,000 people who would benefit from professionally prescribed therapeutic cannabis products and derivatives. 

The overall European regulatory trend favors a social model, exemplified by Malta and Luxembourg, prioritizing public health and controlled access over unrestricted, large-scale commercial retail. The philosophical difference is clear: Europe treats cannabis primarily as a health and social issue, while the United States is cementing its view of cannabis as a massive taxable commodity.

This phase has led to a significant shift toward operational efficiency. The industry, facing high overheads and competitive pricing, saw significant workforce reductions in mature markets as companies sought greater profitability. This has forced firms to double down on technology:

• Technology and AI: Artificial intelligence is being integrated into cultivation to improve yield, manage pests, and automate climate control, reducing labor and material waste.
• Genetics and Products: Research (now easier in the United States) is driving the development of new, high-yield cannabis genetics and targeted cannabinoid profiles (beyond just THC and CBD) for specific pharmaceutical and consumer products.

The trends highlighted in this column clearly demonstrate how the global cannabis industry is migrating toward regulatory models centered on long-term sustainability and responsible use. The massive effort by the United States to formalize its sector through financial and regulatory integration is the loudest signal yet. This is a clear recognition that cannabis companies and entrepreneurs are, above all, drivers of economic growth that will shape the entire region.

2025 marks the end of the "green wave" era driven by mere novelty. It opens the door to a more mature, professional, and business-oriented industry where technology, operational efficiency, scientific evidence, and regulatory recognition will foster formal inclusion into global economic systems. This systemic shift will redefine how the sector perceives itself, leveraging an evolution into a truly global cooperative industry.